The Soft Liver Cataplasm Treatment Of Cirrhosis Of The Liver Qi Stagnation Dampness Clinical Study

Purpose:Through the observation of the difference between Ruanganxiaoshui Cataplasma's Child-Pugh score, quantitative of clinical symptom standard, PCIII, HA, LN,IV-C and adverse reaction before and after treatment of liver cirrhosis, assess the curative effect of Ruanganxiaoshui Cataplasma in treating clinical symptoms of liver cirrhosis, and discuss the mechanism of Ruanganxiaoshui Cataplasma's acupoint application in treating liver cirrhosis.method:Select 60 liver cirrhosis patients qualified for the trial who are randomly divided into two groups: treatment group (30patients) receive Ruanganxiaoshui Cataplasma and basic treatment and control group (30 patients) receive only basic treatment. Duration for curative effect observation of two groups is 30 days. RIA method is applied in PCIII, HA, LN and IV-C test.Results:1. Clinical curative effect assessment: Treatment group: 11 are distinctly effective, 15 are effective, 4 are ineffective, total efficiency rate is 86.7%. Control group: 3 are distinctly effective, 15 are effective, 12 are ineffective, total efficiency rate is 60%. Treatment group is notably superior comparing control group(p<0.05).2. Quantitative of clinical symptom standard: Treatment group: 24.90±5.25 before treatment, 11.37±5.31 after treatment, variation is 13.53±6.02; Control group: 25.07±5.11 before treatment, 15.77±5.48 after treatment, variation is 9.30±4.21. Treatment group is superior to control group, and the difference is significant.3. Child-Pugh score: Treatment group: 8.03±0.93 before treatment, 6.17±0.79 after treatment, variation is 1.87±0.94; Control group: 7.90±0.92 before treatment, 6.47±0.82 after treatment, variation is 1.43±0.77. Child-Pugh score in both groups decline, however, there was no significant.4. Hepatic fibrosis index: variations of PCIII, HA, LN and IV-C are 82.96± 44.31 (μg/L), 99.72±45.72 (μg/L), 62.39±30.53(μg/L) and 48.01±23.60(μg/L). In control group, the results are 51.07±22.53 (μg/L), 62.62±33.17 (μg/L), 43.55±37.37(μg/L) and 35.47±17.50(μg/L). The difference is significant(p<0.05).Conclusion:Ruanganxiaoshui Cataplasma can penetrate via the skin, thus enable the effective ingredients to reach the focus, although Child-Pugh score of treatment group and control group of Ruanganxiaoshui Cataplasma decline, the treatment group is not superior to control group, and holds advantage in hepatic fibrosis index variation and the quantitative of clinical symptom standard, both have statistical significance, and no adverse reaction. It indicates liver cirrhosis of Ruanganxiaoshui Cataplasma treatment is a safe and effective way for clinical application.